Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
22
Participants
Timeline
Start Date
August 31, 2006
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions
DRUG
sunitinib malate
Given orally
Trial Locations (1)
60637
University of Chicago, Chicago
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00387335 - Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter